News
Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 16, 2022
BrainStorm continues to gain insights and perspectives from leading ALS experts as it seeks the optimal path forward to provide broad patient access to NurOwn® Strengthened executive team in...
-
May 12, 2022
Netta Blondheim-Shraga, PhD Appointed as VP R&D Antal Pearl-Lendner, Adv. Appointed as Chief Legal Counsel NEW YORK, May 12, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI),...
-
May 4, 2022
NurOwn-derived exosomes showed more potent anti-inflammatory effects in vitro compared to naïve mesenchymal stem cell-derived exosomes NEW YORK, May 4, 2022 /PRNewswire/ -- BrainStorm Cell...
-
May 3, 2022
Data on MSC-NTF exosome technology at ISCT 2022 and ISEV 2022 conferences NurOwn® CFS biomarker analysis to be presented at ALS Drug Development Summit NEW YORK, May 3, 2022 /PRNewswire/ --...
-
May 2, 2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update...
-
Mar 28, 2022
Brainstorm Cell Therapeutics (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative disease, announced today that the company President and Chief Medical Officer, Ralph...
-
Mar 28, 2022BrainStorm continues to collect and leverage expert feedback as it pursues the optimal path forward to provide broad access to NurOwn® for patients with ALS
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the fiscal year...
-
Mar 14, 2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update...
-
Feb 28, 2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptance of a scientific abstract as a...
-
Feb 15, 2022
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Brazilian Patent Office has granted...
-
Jan 27, 2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D., MHSc, President and...
-
Jan 4, 2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D. MHSc, President and...
-
Dec 27, 2021Three additional doses of NurOwn® will be made available to participants who completed the Expanded Access Protocol
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced plans for a dosing extension of NurOwn® for...
-
Dec 13, 2021Pre-specified and post hoc analyses show NurOwn produced clinical benefits in ALS patients with less severe disease
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publication of Phase 3 clinical data...
-
Dec 7, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, and Catalent (NYSE: CTLT), a global leader in enabling biopharma, cell,...
-
Dec 2, 2021Biomarker data suggest that NurOwn drives significant changes on multiple biomarkers across ALS disease pathways which may be important in achieving clinical outcomes
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that biomarker data on NurOwn® will be presented at the...
-
Nov 29, 2021Pre-specified and post hoc analyses leveraging the published ENCALS model demonstrate a potential treatment effect on ALS disease progression in participants with less severe disease and show that this effect is protected by randomization
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial...
-
Nov 15, 2021BrainStorm remains committed to pursuing the best and most expeditious path forward to facilitate access to NurOwn® for people living with ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced financial results for the quarter ended September 30,...
-
Nov 8, 2021Sidney A. Spector, MD, PhD, appointed Senior VP, Global Strategy and Medical Affairs
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced executive appointments as the company prepares for...
-
Oct 28, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Menghis Bairu, MD, to the company's...
-
Oct 25, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update...
-
Oct 18, 2021Superior clinical and biomarker outcomes demonstrated with NurOwn exosomes compared to MSC exosomes in preclinical ARDS models
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Therapeutic...
-
Oct 14, 2021- Research Demonstrates Safety and Tolerability, Relevant CSF Biomarker Outcomes, and Preliminary Evidence of Efficacy
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multicenter, open label clinical trial of...
-
Oct 6, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF biomarker...
-
Oct 4, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph.D., Executive Vice President and...
-
Oct 1, 2021Presentation to take place at 10:45 a.m. ET (4:45 p.m. CEST) on October 14, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "Phase 2 Safety and...
-
Aug 5, 2021Continuing to assess regulatory strategy for advancing NurOwn® towards potential approval in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended June 30,...
-
Jul 27, 2021GMP certification of three state-of-the-art cleanrooms more than doubles the Company's manufacturing capacity for NurOwn® in Israel
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received Good Manufacturing Practice (GMP)...
-
Jul 26, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update...
-
Jun 15, 2021
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of...
-
May 25, 2021Superior clinical and biomarker outcomes demonstrated with NurOwn exosomes compared to MSC exosomes in Preclinical ARDS Model
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular...
-
Apr 26, 2021- Positive Phase 2 data demonstrate the potential of NurOwn® as a treatment for progressive MS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31,...
-
Apr 19, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update...
-
Mar 24, 2021NurOwn® was shown to be safe and well tolerated
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial...
-
Feb 23, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that members of the management team will...
-
Feb 22, 2021FDA recommended generating additional clinical data to meet FDA's BLA requirements
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from...
-
Feb 9, 2021FDA provided guidance on introducing semi-automated manufacturing in the future for commercialization
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently concluded a Type C meeting with...
-
Feb 4, 2021- Company met with the FDA to present phase 3 data and is in ongoing discussions with the FDA to identify agreed upon regulatory pathways that may support NurOwn's future approval in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the fiscal year ended December 31,...
-
Jan 28, 2021
BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases,...
-
Jan 20, 2021Intratracheal administration of NurOwn® derived exosomes significantly improves lung function and histology in a mouse model of acute respiratory distress syndrome (ARDS)
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical...
-
Dec 28, 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the following letter from its Chief Executive Officer,...
-
Dec 18, 2020Topline clinical trial results expected by the end of the first quarter 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that all dosing has been completed in the ongoing...
-
Dec 14, 2020NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today the initiation...
-
Nov 23, 2020- Dr. Merit Cudkowicz and Dr. Ralph Kern presentation will be featured in Oral Presentation in the Clinical Trials Platform Session
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that results from the Company's placebo...
-
Nov 17, 2020Clinical trial did not meet statistical significance in primary efficacy endpoint
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized,...
-
Oct 26, 2020RR&D to lead site selection and design
Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for...
-
Oct 22, 2020
SOMERSET, N.J. and New York – October 22, 2020 — Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs,...
-
Oct 19, 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, "MSC-NTF...
-
Oct 15, 2020BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate UpdatePivotal Phase 3 ALS trial remains on track for top-line data readout by the end of November 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the third quarter ended September...
-
Oct 12, 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Stacy Lindborg, Ph.D., Executive Vice President...
Tools
Investors
- Overview
- News
- Events & Presentations
- Stock Information
- Financial Reports & Filings
- Corporate Governance